TNF involvement and anti-TNF therapy of reactive and unclassified arthritis.

A growing body of evidence shows that tumor necrosis factor (TNF) alpha, a pro-inflammatory cytokine involved in the pathogenesis of rheumatoid arthritis (RA), is also involved in the pathogenesis of reactive and unclassified arthritis. Elevated levels of TNF-alpha and other pro-inflammatory cytokines are seen in these inflammatory arthropathies. The clinical effect on a potential underlying infection is not known, but several studies have suggested at least short-term effectiveness and safety of anti-TNF-alpha therapy in reactive and unclassified arthritis.

[1]  E. Veys,et al.  Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up , 2002, Annals of the rheumatic diseases.

[2]  P. Emery,et al.  Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. , 2001, Arthritis and rheumatism.

[3]  H. Gérard,et al.  Chromosomal DNA from a variety of bacterial species is present in synovial tissue from patients with various forms of arthritis. , 2001, Arthritis and rheumatism.

[4]  F. Wolfe,et al.  Lessons from an international survey of paper cases of 10 real patients from an early arthritis clinic. CRI (Club Rhumatismes et Inflammation) Group. , 2001, The Journal of rheumatology.

[5]  J. S. Cohen.  Clinical and laboratory improvement in ankylosing spondylitis after treatment with etanercept: a case report. , 2000, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[6]  H. Schumacher.  The end of ‘disease’ as a simple concept , 2000, Current rheumatology reports.

[7]  P. Duray,et al.  Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis , 2000, Arthritis research.

[8]  Schlaak,et al.  Tumour necrosis factor (TNF) production by T cell receptor‐primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis , 1999, Clinical and experimental immunology.

[9]  M. Leirisalo-Repo,et al.  Modulation of peripheral blood mononuclear cell activation status during Salmonella-triggered reactive arthritis. , 1999, Arthritis and rheumatism.

[10]  H. Gérard,et al.  Gamma Interferon and Interleukin-10 Gene Expression in Synovial Tissues from Patients with Early Stages ofChlamydia-Associated Arthritis and Undifferentiated Oligoarthritis and from Healthy Volunteers , 1999, Infection and Immunity.

[11]  J. Heesemann,et al.  Effect of cytokines on invasion and survival of Yersinia in primary human fibroblasts , 1999, Medical Microbiology and Immunology.

[12]  J. Ilonen,et al.  Tumour necrosis factor microsatellites in reactive arthritis. , 1998, British journal of rheumatology.

[13]  E. Straube,et al.  Secretion of cytokines by human synoviocytes during in vitro infection with Chlamydia trachomatis. , 1998, The Journal of rheumatology.

[14]  H. Zeidler,et al.  Undifferentiated arthritis and reactive arthritis. , 1998, Current opinion in rheumatology.

[15]  C. R. Wang,et al.  Measurement of synovial tumor necrosis factor-alpha in diagnosing emergency patients with bacterial arthritis. , 1997, The American journal of emergency medicine.

[16]  H. Gérard,et al.  Chlamydia trachomatis Can Persist in Joint Tissue After Antibiotic Treatment in Chronic Reiter's Syndrome / Reactive Arthritis , 1997, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[17]  H. Schumacher,et al.  In vivo gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis. , 1997, Proceedings of the Association of American Physicians.

[18]  H. Gérard,et al.  Ultrastructural and molecular analyses of the persistence of Chlamydia trachomatis (serovar K) in human monocytes. , 1997, Microbial pathogenesis.

[19]  H. Schumacher,et al.  A simple nested RT-PCR method for quantitation of the relative amounts of multiple cytokine mRNAs in small tissue samples. , 1996, Journal of immunological methods.

[20]  H. Gérard,et al.  Comparison of synovial tissue and synovial fluid as the source of nucleic acids for detection of Chlamydia trachomatis by polymerase chain reaction. , 1996, Arthritis and rheumatism.

[21]  A. Hudson,et al.  Case Report: In Situ Hybridization for Detection of Inapparent Infection With Chlamydia trachomatis in Synovial Tissue of a Patient With Reiter's Syndrome , 1995, The American journal of the medical sciences.

[22]  J. Whittum-Hudson,et al.  In Situ Hybridization for Detection of Inapparent Infection With Chlamydia trachomatis in Synovial Tissue of a Patient With Reiter’s Syndrome , 1995 .

[23]  A. Hudson,et al.  Alteration of Chlamydia trachomatis biologic behavior in synovial membranes. Suppression of surface antigen production in reactive arthritis and Reiter's syndrome. , 1995, Arthritis and rheumatism.

[24]  C. Zhang,et al.  Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria, and bacterial polymers , 1995, Infection and immunity.

[25]  W. Beatty,et al.  Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence , 1994, Infection and immunity.

[26]  W. Beatty,et al.  Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Espinoza,et al.  Chlamydia-induced reactive arthritis. , 1993, Rheumatic diseases clinics of North America.

[28]  A. Hudson,et al.  Molecular evidence for the presence of chlamydia in the synovium of patients with Reiter's syndrome. , 1992, Arthritis and rheumatism.

[29]  D. Wallach,et al.  Inhibition of Chlamydia trachomatis growth by recombinant tumor necrosis factor , 1988, Infection and immunity.

[30]  D. Bennahum,et al.  Navajo arthritis--an unusual, acute, self limited disease. , 1971, Arthritis and rheumatism.

[31]  M. Feldmann,et al.  Role of pro-inflammatory cytokines in rheumatoid arthritis , 2004, Springer Seminars in Immunopathology.

[32]  J. Braun,et al.  Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. , 2002, The Journal of rheumatology.

[33]  B. Combe,et al.  Outcomes in patients with incipient undifferentiated arthritis. , 2000, Joint, bone, spine : revue du rhumatisme.

[34]  H. Zeidler,et al.  Undifferentiated arthritis in an early synovitis out-patient clinic. , 1995, Clinical and experimental rheumatology.